Recon: FDA advisors back Amylyx ALS drug after second adcomm; Revance’s Botox rival wins FDA approval
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy